The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an
antibody or
antigen-binding fragment thereof that specifically binds to
proprotein convertase subtilisin /
kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an
antibody that specifically binds to
angiopoietin-like
protein 3 (ANGPTL3). The combination of an anti-PCSK9
antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as
hyperlipidemia, hyperlipoproteinemia and
dyslipidemia, including
hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal
lipid metabolism is a
risk factor, such as cardiovascular diseases.